Biogen (BIIB) Shares are Up 0.75%

Biogen (BIIB) : Traders are bullish on Biogen (BIIB) as it has outperformed the S&P 500 by a wide margin of 14.46% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.81%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.75% in the last 1 week, and is up 18.31% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 10.43% and the 50-Day Moving Average is 12.03%. Biogen Inc. is up 5.43% in the last 3-month period. Year-to-Date the stock performance stands at -5.36%.


Biogen (NASDAQ:BIIB): stock turned positive on Friday. Though the stock opened at $288.85, the bulls momentum made the stock top out at $290.46 level for the day. The stock recorded a low of $286.8 and closed the trading day at $289.93, in the green by 0.31%. The total traded volume for the day was 1,338,487. The stock had closed at $289.03 in the previous days trading.

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.